Emerging Treatments: Cardiovascular Disease

Ischemic heart disease remains the leading cause of death globally and attracts significant investment by pharma and biotech. This panel will explore the evolving pharmaceutical pipeline for cardiovascular disease, focusing on promising advances such as Lipoprotein(a) reduction, oral PCS-K9s, Factor XI inhibitors, the role of GLP-1s in cardiovascular health, CETP inhibitors, and aldosterone synthase inhibitors (ASIs). The session will examine how these breakthroughs may shift clinical practice and improve long-term outcomes for patients living with CVD.